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The Trithorax protein Ash1L promotes myoblast
fusion by activating Cdon expression
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Myoblast fusion (MF) is required for muscle growth and repair, and its alteration contributes
to muscle diseases. The mechanisms governing this process are incompletely understood,
and no epigenetic regulator has been previously described. Ash1L is an epigenetic activator
belonging to the Trithorax group of proteins and is involved in FSHD muscular dystrophy,
autism and cancer. Its physiological role in skeletal muscle is unknown. Here we report
that Ash1L expression is positively correlated with MF and reduced in Duchenne muscular
dystrophy. In vivo, ex vivo and in vitro experiments support a selective and evolutionary
conserved requirement for Ash1L in MF. RNA- and ChIP-sequencing indicate that Ash1L
is required to counteract Polycomb repressive activity to allow activation of selected
myogenesis genes, in particular the key MF gene Cdon. Our results promote Ash1L as an
important epigenetic regulator of MF and suggest that its activity could be targeted to
improve cell therapy for muscle diseases.
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Cell fusion is a fundamental process required for sexualreproduction and for the development of many bodytissues1,2. During fertilization, the fusion of sperm and egg
leads to the formation of a diploid cell3,4. Macrophages undergo
fusion events to form osteoclasts during bone development5.
Also, the genetic reprogramming of somatic cells could occur
following stem cell fusion6. Besides these important examples, a
speciﬁc and tightly regulated type of fusion is crucial for skeletal
muscle tissue formation, growth, and repair1,7,8. During
embryonic development, mononucleated muscle cells, termed
myoblasts, undergo massive proliferation, providing the required
number of precursor cells to build skeletal muscles. Subsequently,
they exit the cell cycle, start to differentiate and fuse with one
another to generate multinucleated and fully differentiated
myoﬁbers7,8. This process continues for the ﬁrst 3 weeks of
postnatal life, in mice9. In the adulthood at steady state, myoblast
fusion events are sporadic but necessary for muscle regeneration.
In response to muscle damage, muscle stem (satellite) cells, which
normally reside at the periphery of the mature ﬁber in a quiescent
state, activate, proliferate, and fuse to reconstruct the damaged
muscle10–14. Notably, defects in myoblast fusion contribute to the
pathogenesis of an increasing number of muscle diseases15–20.
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Recognition and adhesion between fusion partners is an early
and key event in myoblast fusion21. Accordingly, the majority
of the proteins involved in myoblast fusion identiﬁed so far are
adhesion proteins, transmembrane lipids, intracellular signaling,
or adaptor proteins22–25. Among these, the immunoglobulin-like
and ﬁbronectin type III domains protein Cdon (cell-adhesion-
molecule-related/downregulated by oncogenes) is a member
of a cell-surface receptor complex that mediates cell–cell inter-
actions between muscle precursor cells and positively regulates
myogenesis26,27.
While we know extensively about the structural and signaling
components required for myoblast fusion, the gene expression
regulation underlying this important process is poorly under-
stood. A few transcription factors activating myoblast fusion
have been described28–31; however, an identiﬁcation of fusion-
regulated target genes on a genome-wide scale is mostly lack-
ing28–31. Importantly, no epigenetic regulator of myoblast fusion
has ever been deﬁned.
Absent, small, or homeotic discs like 1 (Ash1L) is a Trithorax
group protein that positively regulates gene transcription by
counteracting Polycomb group (PcG) protein-mediated silen-
cing32. Ash1L di-methylates histone H3 lysine 36 to produce
H3K36me233, a histone mark associated with transcriptional
activation and enriched at transcription start sites (TSS)34. Ash1L
is involved in several pathological conditions, including auto-
immune disease, autism, and cancer34–40. Despite its involvement
in facioscapulohumeral (FSHD) muscular dystrophy41, the phy-
siological role of Ash1L in skeletal muscle is unknown.
We found an evolutionarily conserved requirement for Ash1L
in myoblast fusion. Combining genome-wide approaches with
gain-of-function and loss-of-function assays, we identiﬁed Cdon
as a direct Ash1L target required for Ash1L-mediated myoblast
fusion activation. Altogether, our results promote Ash1L as a
crucial epigenetic regulator of myoblast fusion.
Results
Ash1L expression positively correlates with myoblast fusion.
To begin investigating the physiological role of Ash1L in the ske-
letal muscle, we evaluated its expression in three crucial processes:
muscle development, muscle regeneration, and in vitro muscle
differentiation (Fig. 1). During murine prenatal development and
adulthood, Ash1L expression resulted maximal in fetal skeletal
muscles, when myoblast fusion events are most frequent11, and was
progressively and signiﬁcantly reduced reaching a minimum at
P28, when myoblast fusion is normally off (Fig. 1a). Intriguingly,
the key myoblast fusion factor Myomaker displayed a similar
expression pattern (Fig. 1a)22,42. On the contrary, the gene
encoding for the adult skeletal muscle myosin Myh4 showed an
opposite trend, reaching a maximum when myoblast fusion is over
(Fig. 1a). In adulthood at steady state, myoblast fusion is nearly
absent, but it is reactivated during regeneration in response to
muscle damage43. To assess Ash1L expression during muscle
regeneration, we analyzed tibialis anterior muscle of 8-week-old
mice after cardiotoxin (CTX) injury (Fig. 1b). Compared to
uninjured muscle, Ash1L expression was signiﬁcantly upregulated
during the initial phase of muscle regeneration (day 5), and
downregulated at day 10, when myoblast fusion decreases43 simi-
larly to Myomaker44. During in vitro myogenesis, we found that
Ash1L upregulation occurred just after the induction of differ-
entiation (day 1) (Fig. 1c), and simultaneously with myoblast
fusion activation45. A key step for myoblast fusion activation is
cell–cell contact46–48. Interestingly, we found that cell conﬂuence
in proliferation media was sufﬁcient to signiﬁcantly induce Ash1L
expression (Fig. 1d). Myoblast fusion defects have been described
in several muscle diseases15–17,49–55 including Duchenne muscular
dystrophy (DMD)56,57. Inspection of the GEO database (http://
www.ncbi.nlm.nih.gov/geo/info/proﬁles.html) revealed that Ash1L
expression is signiﬁcantly downregulated in muscle tissue from
both DMD patients and the DMD mouse model mdx, which we
conﬁrmed by real-time quantitative reverse transcription
PCR (RT-qPCR) (Supplementary Figure 1). Collectively, our
results indicate that the expression of Ash1L is positively correlated
to myoblast fusion and is signiﬁcantly downregulated in DMD.
Ash1L is speciﬁcally required for myoblast fusion. We used
embryonic stem cells containing a gene trap cassette inserted in
intron 1 of the mouse Ash1L gene to generate mice lacking Ash1L
(Ash1L GT). Unlike a previous report showing that the majority
of Ash1L GT mice survived into adulthood, although not at a
Mendelian ratio58, most of our independently generated Ash1L
GT mice were not born alive and the remaining animals displayed
full lethality by P8 (Supplementary Figure 2), possibly due to
the different procedures utilized and the degree of backcrossing
of the different strains (see Methods). We hence decided to
analyze Ash1L GT mice at embryonic day 18.5 when Ash1L
expression and myoblast fusion are high. While we found no
signiﬁcant alteration in the number of muscle ﬁbers, Gomori-
trichrome staining of quadricep transverse cryosections revealed
a signiﬁcantly reduced myoﬁber cross-sectional area (CSA) in
Ash1L GT mice compared to wild-type mice (Fig. 2a). Interest-
ingly, longitudinal sections showed that the number of myonuclei
per individual myoﬁber is signiﬁcantly lower in Ash1L GT mice
compared to wild-type mice (Fig. 2b).
To elucidate the muscle formation defect of Ash1L GT mice,
we compared ex vivo satellite cell-derived myoblast cultures from
hindlimbs of wild-type and Ash1L GT mice isolated at the
embryonic stage of 18.5. While the percentage of myosin heavy
chain (Mhc)-positive cells displayed no signiﬁcant alteration, the
fusion index of Ash1L GT myoblasts was signiﬁcantly lower
Fig. 1 Correlation between Ash1L expression and myoblast fusion. a Ash1L expression during muscle development. RT-qPCR analysis on muscle tissue from
hindlimbs of mice from the embryonic stage E16.5 to adulthood (p28). Expression analysis of Myomaker, as a positive fusion gene, and adult myosin
(Myh4) as a positive control for adult stages. Unpaired two-tailed t test. Conﬁdence intervals 95%. n= 6. b Ash1L expression in regenerating muscle tissue.
RT-qPCR analysis of Ash1L expression in tibialis anterior of wild-type adult mice, untreated (UNT), or 5 and 10 days after cardiotoxin (CTX) injection (left
panel). Immunoﬂuorescence for Ash1L (in green) and nuclear staining (Hoechst), in transverse cryosections from the tibialis anterior muscles of injured
wild-type mice, 5 days after cardiotoxin injection (CTX 5 days) compared to untreated controls (Unt). Scale bar, 50 μm. Magniﬁcation ×65. Arrows
indicate the Ash1L-positive nuclei. Unpaired two-tailed t test. Conﬁdence intervals 95%. n= 4. c Ash1L protein level during in vitro muscle differentiation.
Immunoblot of C2C12 cells at days 0 and 1, and densitometric analysis of Ash1L signal relative to vinculin as housekeeping protein (left panel).
Immunoﬂuorescence for Ash1L (in green) and nuclear staining (Hoechst), in C2C12 cells at days 0 and 1 of in vitro muscle differentiation. Scale bar,
100 μm. Magniﬁcation ×20. Paired two-tailed t test. Conﬁdence intervals 95%. Data are the mean for three independent experiments. d Ash1L protein level
in proliferating myoblasts vs. conﬂuent cells. Comparison between proliferating myoblasts (P) and conﬂuent cells (C). Paired two-tailed t test. Conﬁdence
intervals 95%. Data are the mean for three independent experiments. Source data are provided as a Source Data ﬁle. *p≤ 0.05, **p≤ 0.01, ***p≤
0.001, ****p≤ 0.0001. NS not signiﬁcant
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compared to controls (Fig. 3a). Moreover, individual Ash1L GT
myoﬁbers presented a signiﬁcantly reduced number of myonuclei
compared to controls (Fig. 3a).
To further support our ﬁndings, we performed acute Ash1L
knockdown (KD) in C2C12 muscle cells. Similar to Ash1L GT,
Ash1L KD caused no signiﬁcant alteration in the percentage of
Mhc-positive myoﬁbers, but a signiﬁcant reduction of the fusion
index and the number of nuclei per myoﬁber (Fig. 3b).
Importantly, similar results were obtained in human primary
myoblasts (Fig. 3c), indicating that Ash1L is evolutionary
required for myotube formation.
Muscle formation requires myoblast proliferation, migration,
differentiation, and fusion59. In principle, dysfunction of one or
more of these processes could contribute to aberrant myotube
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Fig. 2 Ash1L GT mice display muscle hypoplasia. a Gomori-trichrome staining of transverse cryosections from wild-type (WT) and Ash1L GT mice, at
embryonic stage E18.5 (upper panel). Quantiﬁcation of: the total number of myoﬁbers and myoﬁbers cross-sectional area (CSA) (lower panel). n= 3. Scale
bar, 100 µm, magniﬁcation ×20. Unpaired two-tailed t test. Conﬁdence intervals 95%. Results come from six biological replicates. b Immunoﬂuorescence
for laminin (in green) and nuclear staining (Hoechst) in longitudinal cryosections from wild-type (WT) and Ash1L GT mice, at the embryonic stage of E18.5
(left panel). Quantiﬁcation of the number of myonuclei normalized on myoﬁber length in mm (myonuclei/myoﬁbers) (right panel). Scale bar, 100 µm,
magniﬁcation ×20. Unpaired two-tailed t test. Conﬁdence intervals 95%. Results come from seven biological replicates. Source data are provided as a
Source Data ﬁle. *p≤ 0.05
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formation in the absence of Ash1L. As shown in Supplementary
Figure 3a, Ash1L-depleted cells did not present either prolifera-
tion or doubling time alterations compared to control cells.
Time-lapse microscopy excluded also a signiﬁcant migration
impairment of Ash1L-KD myoblasts (Supplementary Figure 3b).
Finally, the myogenic transcription factors MyoD and myogenin,
and the muscle-speciﬁc marker desmin were expressed normally
in Ash1L-KD cells (Supplementary Figure 3c), suggesting that
Ash1L is not required to activate the muscle differentiation
program. These ﬁndings imply that myoblasts depleted of Ash1L
can proliferate, migrate, and activate muscle-speciﬁc gene
expression, while are selectively defective in their ability to fuse.
Identiﬁcation of direct Ash1L targets in muscle cells. In order
to deﬁne the molecular mechanism through which Ash1L acti-
vates myoblast fusion, we performed RNA-sequencing comparing
Ash1L KD to control C2C12 myoblasts. We identiﬁed 135 dif-
ferentially expressed genes (false discovery rate (FDR) <0.05)
(Supplementary Data 1). In line with the known involvement of
Ash1L in transcriptional activation, most of the differentially
expressed genes resulted downregulated (100/135, 74%), whereas
only a few genes resulted upregulated (35/135, 26%). The
downregulated genes returned several intriguing categories rela-
ted to transcription activation, muscle differentiation, and cell
adhesion (Fig. 4).
To determine which genes were directly impacted by Ash1L,
we performed chromatin immunoprecipitation followed by
sequencing (ChIP-seq) to determine Ash1L genomic targets
(Supplementary Data 2). Our analysis revealed extensive Ash1L
occupancy at the gene bodies of its target genes with an
enrichment near TSS (Fig. 5a, b), consistently with previous
reports2,34,60–62. In the absence of chromatin state map
(ChromHMM) data available for murine muscle cells, we
compared our Ash1L peaks with chromatin state maps of
available mouse tissues from ENCODE63. As expected, Ash1L
resulted enriched at regions deﬁned as active promoters or active
enhancers (Fig. 5c). Intriguingly, we observed an enrichment of
Ash1L also in regions characterized by the presence of the PcG-
deposited histone mark H3K27me3 and deﬁned as repressed,
poised promoters, or poised enhancers (Fig. 5c).
Ash1L counteracts Polycomb activity through the deposition of
H3K36me260,64–67. As expected, by ChIP-seq we found that the
levels of H3K36me2 were higher on expressed genes compared to
not expressed genes as detected by RNA-sequencing (RNA-seq)
in C2C12 (Mann–Whitney p value < 2 × 10–6; Fig. 5d). Intrigu-
ingly, among expressed genes the levels of H3K36me2 were
signiﬁcantly higher on the genes associated with Ash1L ChIP-seq
peaks (Mann–Whitney p value= 4.2 × 10–11; Fig. 5d), supporting
a role of Ash1L in their activation.
Next, we used gene set enrichment analysis (GSEA) to correlate
the genes displaying Ash1L ChIP-seq peaks to the transcriptional
downregulation upon Ash1L depletion. Leading-edge analysis
allowed us to identify 45 direct Ash1L targets (normalized
enrichment score (NES)=−2.35, FDR < 0.001) (Fig. 6a)
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Fig. 3 Effects of Ash1L ablation on myoblast fusion. a Primary myoblasts isolated from Ash1L GT mice display a fusion defect. Immunoﬂuorescence for
myosin heavy chain (in green) and nuclear staining (Hoechst) in primary cultures from wild-type (WT) and Ash1L GT mice at E18.5 stage, after inducing
differentiation for 48 h. Scale bar, 100 µm. RT-qPCR analysis of Ash1L expression, validating Ash1L ablation in GT mice compared to wild-type mice.
Percentage of Mhc-positive cells, calculated in comparison with the total number of nuclei. Fusion index, calculated as the number of nuclei present in
myotubes (Mhc-positive and containing at least three nuclei) in comparison with the total number of nuclei. Nuclei distribution, calculated as the frequency
of Mhc-positive cells containing the indicated number of nuclei. Unpaired two-tailed t test. Conﬁdence intervals 95%. Results come from ﬁve biological
replicates. b Ash1L knockdown leads to a muscle fusion defect. Immunoﬂuorescence for myosin heavy chain and nuclear staining in C2C12 cells transfected
with non-targeting (NS) and Ash1L siRNAs (Ash1L KD) and differentiated for 3 days. Scale bar, 100 µm. Ash1L expression, percentage of Mhc-positive cells,
fusion index, and nuclei distribution evaluated as described above. Unpaired two-tailed t test. Conﬁdence intervals 95%. Results come from three biological
replicates. c Muscle fusion defect upon Ash1L knockdown is conserved in human. Immunoﬂuorescence for myosin heavy chain and nuclear staining in
human primary myoblast transfected with non-targeting (human NS) and Ash1L siRNAs (human Ash1L KD) and differentiated for 4 days. Scale bar, 100 µm.
Ash1L expression, percentage of MHC-positive cells, fusion index, and nuclei distribution evaluated as described above. Unpaired two-tailed t test.
Conﬁdence intervals 95%. Results come from three healthy subjects. Source data are provided as a Source Data ﬁle. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001. NS
not signiﬁcant
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(Supplementary Data 3). Functional enrichment analysis returned
an even stronger signiﬁcance for categories involved with the
positive regulation of myogenesis (Fig. 6b). Accordingly, Ash1L
targets resulted also signiﬁcantly enriched for genes activated
during muscle differentiation (p= 0.028) (Supplementary Data 4).
In line with the ability of Ash1L to positively regulate gene
transcription by counteracting PcG-mediated silencing52,60,64–66,
ChIP enrichment analysis unveiled that the majority of Ash1L
targets (39 out of 45) are also Polycomb targets (Supplementary
Data 5).
In agreement with Ash1L-mediated activation, all the direct
Ash1L targets tested were found signiﬁcantly downregulated by
Ash1L depletion in mouse and human muscle cells (Supplemen-
tary Figure 4a). Moreover, ChIP followed by real-time quantita-
tive PCR (ChIP-qPCR) showed that Ash1L KD causes a speciﬁc
reduction in Ash1L enrichment in the genomic regions of all
these genes (Supplementary Figure 4b), strongly supporting the
validity of our ChIP-seq results.
Collectively, our analyses promote Ash1L as a positive
regulator of genes important for muscle formation.
Ash1L promotes myoblast fusion through Cdon regulation. To
provide a possible molecular mechanism for the speciﬁc myoblast
fusion defect observed upon Ash1L depletion, we inspected the
list of direct Ash1L target genes. Among them, the only one with
a known role in myoblast fusion was Cdon. The Cdon gene
encodes for a cell-surface receptor mediating cell–cell interactions
between muscle precursor cells and positively regulating myoblast
fusion68. Similar to mice lacking Ash1L, at E18.5 Cdon-knockout
(KO) mice show smaller muscles compared to controls68.
Moreover, like Ash1L GT myoblasts, Cdon-null primary myo-
blasts fail to fuse into myotubes68. We found that in vivo during
muscle development or in response to muscle damage (Fig. 7a, b),
and in vitro during muscle differentiation69 (Fig. 7c), Cdon dis-
plays an expression pattern almost identical to that of Ash1L.
Intriguingly, Cdon expression was signiﬁcantly reduced in muscle
tissue from Ash1L GT mice compared to wild-type mice, and in
murine C2C12 or human primary muscle cells KD for Ash1L
compared to controls (Fig. 7d, e). Our ChIP-seq results indicate a
peak of Ash1L enrichment at the Cdon TSS (Fig. 7f). By ChIP-
qPCR, we found a speciﬁc Ash1L enrichment near the Cdon TSS,
which was signiﬁcantly reduced compared to controls upon
Ash1L KD (Fig. 7f). These results indicate that Cdon is a direct
and speciﬁc Ash1L target.
To evaluate the biological relevance of Cdon activation by
Ash1L, we expressed Cdon in Ash1L-KD muscle cells. After
3 days of differentiation, we performed immunoﬂuorescence
staining for Mhc and we evaluated both the fusion index and the
number of nuclei per myoﬁber. While the fusiogenic capability of
Ash1L-KD cells was signiﬁcantly reduced compared to controls,
cells depleted of Ash1L and concomitantly expressing Cdon were
not signiﬁcantly different from controls (Fig. 8). This evidence
strongly supports that Cdon expression is sufﬁcient to rescue the
myoblast fusion defect caused by Ash1L ablation. Altogether, our
ﬁndings indicate that Cdon is a key target gene activated by
Ash1L to promote myoblast fusion.
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Discussion
Using a combination of cell biology, transcriptomics, genomics,
and genetic analyses we show that Ash1L is evolutionarily
required for myoblast fusion, while it is dispensable for myoblast
proliferation, migration, and differentiation. In particular, our
results suggest that muscle cells lacking Ash1L can differentiate
and fuse to form the initial multinucleated myotube, but are
defective in the further fusion of myoblasts with myotubes or
myotubes with myotubes.
Myoblast fusion is a complex process required for muscle
development, postnatal muscle growth, and adult muscle regen-
eration. Elegant studies in Drosophila and vertebrates have
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identiﬁed many secreted, membrane, signaling, or cytoskeletal
proteins belonging to the myoblast fusion machinery8,10. On the
contrary, only few transcription factors involved in myoblast
fusion are known28–31. Notably, no epigenetic regulator of
myoblast fusion has ever been described.
Ash1L (Kmt2h) is a histone methyltransferase belonging to the
Trithorax group. It positively regulates gene transcription by
attaching two methyl groups to H3K36 and counteracting PcG-
mediated gene silencing32. We found that the expression of Ash1L
is positively correlated to myoblast fusion in vivo and in vitro.
Intriguingly, Ash1L ablation causes a selective myoblast fusion
defect in murine and human muscle cells. Accordingly, Ash1L GT
mice display smaller muscles and fewer nuclei per myoﬁbers
likely due to a reduced myoblast fusion.
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In agreement with its role in transcriptional activation, we
found that Ash1L is enriched in active regions of the muscle cells
genome, near the TSS of genes presenting also high levels of
H3K36me2, and we observed mostly gene downregulation fol-
lowing Ash1L depletion. Genomic regions associated to Ash1L are
also enriched for regulatory sequences that have been deﬁned by
the presence of the Polycomb-dependent histone mark
H3K27me363. Intriguingly, we found that the genes down-
regulated upon Ash1L-KD are enriched for known Polycomb
targets. By combining RNA-seq and ChIP-seq, we identiﬁed 45
direct Ash1L targets. They are enriched for genes induced upon
muscle differentiation and with an important role in myogenesis.
Given the known role of Ash1L in counteracting Polycomb-
repressive activity32, it is tempting to speculate that the increase
in Ash1L expression at the early phase of muscle differentiation
could allow for the expression of speciﬁc Polycomb targets
required for muscle differentiation.
Cell–cell contact is required for myoblast fusion and strongly
stimulates myogenesis through the activation of promyogenic
signal transduction pathways21. A key factor in cell contact-
dependent signaling during myoblast fusion is Cdon, a multi-
functional cell-surface protein serving as coreceptor for
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N-cadherin, neogenin, Hedgehog, and Wnt pathways21. Cdon is a
Polycomb target (Supplementary Data 5), is upregulated during
muscle differentiation70 and is the only direct Ash1L target gene
with a known role in myoblast fusion68. We found that Cdon
parallels Ash1L expression during muscle development and
regeneration. Moreover, Cdon is signiﬁcantly downregulated in
muscles of Ash1L GT mice and upon Ash1L depletion in mouse
and human muscle cells. Cdon-KO mice display smaller muscle
ﬁbers68, as we observed in Ash1L GT mice. Furthermore, primary
myoblasts isolated from both Cdon68 and Ash1L GT mice display
a myoblast fusion defect. Importantly, we found that Cdon
expression is sufﬁcient to rescue the myoblast fusion defect of
Ash1L-KD cells indicating that (at least in vitro) Cdon is a key
target through which Ash1L regulates myoblast fusion. Future
work is required to understand the relevance of the other direct
Ash1L targets that we identiﬁed in muscle.
In vitro, myotube formation is generally obtained by growing
myoblasts until near conﬂuence in mitogen-rich medium, fol-
lowed by a switch to mitogen-poor medium. Although the
reduction of growth factors is an important differentiation signal,
cell conﬂuency itself is strongly promyogenic21. Intriguingly, we
found that cell conﬂuence is sufﬁcient to strongly activate Ash1L
expression even in the presence of a mitogen-rich medium. In the
future, it would be interesting to determine which signaling
pathway activated by high myoblast cell density is involved in
Ash1L activation.
Ash1L is not a sequence-speciﬁc DNA-binding protein. Hence,
the association of Ash1L to speciﬁc genomic regions is likely
Fig. 7 The fusion gene Cdon is a direct target of Ash1L. Cdon expression positively correlates with Ash1L during muscle development (a) and regeneration
(b). RT-qPCR analysis on muscle tissue from hindlimbs of mice from the embryonic stage E16.5 to adulthood and in tibialis anterior of wild-type adult mice,
untreated (UNT), or 5 and 10 days after cardiotoxin (CTX) injection. Unpaired two-tailed t test. Conﬁdence intervals 95%. n= 6 (a), n= 4 (b). c Cdon
protein level during in vitro muscle differentiation and in proliferating myoblasts vs. conﬂuent cells. Immunoblot of C2C12 cells at days 0 and 1, and
densitometric analysis of Cdon signal relative to vinculin as housekeeping protein (left panel). Comparison between proliferating myoblasts (P) and
conﬂuent cells (C) (right panel). Paired two-tailed t test. Conﬁdence intervals 95%. Data are the mean for three independent experiments. d RT-qPCR
analysis comparing Cdon expression in the presence and absence of Ash1L in three different models: muscle tissue from hindlimbs of wild-type (WT) and
Ash1L GT embryos at E18.5, C2C12 cells transfected with non-targeting (NS) or Ash1L siRNAs (Ash1L KD), and human primary cells transfected with non-
targeting or Ash1L siRNAs, and collected at day 1 of differentiation. Unpaired two-tailed t test. Conﬁdence intervals 95%. n= 6 (muscle tissue), four
independent experiments (C2C12 cells), and three independent healthy subjects (human samples). e Western blotting analysis showing Cdon
downregulation in muscle tissue from hindlimbs of Ash1L GT embryos at E18.5 compared to wild type (WT), and in C2C12 cells transfected with Ash1L
siRNAs (Ash1L KD) compared to control (NS). Densitometric analysis of both Ash1L and Cdon signals relative to vinculin as housekeeping protein are
reported on the right. Paired one-tailed t test. Conﬁdence intervals 95%. n= 3 (muscle tissue), three independent experiments (C2C12 cells). f Ash1L
speciﬁcally binds to Cdon genomic region. Genome browser representation of Ash1L ChIP-seq peaks (from three replicates), at Cdon genomic region.
Relative positions of both positive and negative regions are shown at the bottom (left). Chromatin immunoprecipitation on C2C12 cells transfected with
non-targeting (NS) or Ash1L siRNAs (Ash1L KD), and ﬁxed at day 1 of differentiation, using Ash1L antibody and IgG as a negative control. qPCR analysis on
positive and negative regions according to ChIP-sequencing results (right). Unpaired two-tailed t test. Conﬁdence interval 95%. n= 3. Source data are
provided as a Source Data ﬁle. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001
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Fig. 8 Cdon expression rescues fusion defects caused by Ash1L knockdown. a Immunoﬂuorescence for myosin heavy chain and nuclear staining in C2C12
cells treated with two consecutive rounds of transient transfections: non-targeting (NS) or Ash1L siRNAs (Ash1L KD), and empty vector (EV) or Cdon-
expressing vector (Cdon OE), before inducing differentiation for 3 days (left). Scale bar, 100 µm. b RT-qPCR analysis of Ash1L and Cdon expression in C2C12
cells transfected with: empty vector plus non-targeting siRNAs (EV+NS), empty vector plus Ash1L siRNAs (EV+ Ash1L KD), Cdon-expressing vector plus
non-targeting siRNAs (Cdon OE+NS), and Cdon-expressing vector+Ash1L siRNAs (Cdon OE+ Ash1L KD). c Fusion index and nuclei distribution for each
condition were calculated as described for Fig. 3. Unpaired two-tailed t test. Conﬁdence intervals 95%. n= 3. Source data are provided as a Source Data
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mediated by gene-speciﬁc recruiters. We previously reported that
the long non-coding RNA (lncRNA) DBE-T directly binds to
Ash1L and recruits it to the FSHD muscular dystrophy locus for
the activation of key disease genes41. By analogy, it would thus be
interesting to ﬁnd out whether additional lncRNAs are involved
in Ash1L recruitment to its target genes identiﬁed in the present
study.
The regulation of myoblast fusion is relevant for understanding
the pathogenesis15,17,53 and treatment of several muscle dis-
orders. One of the muscular diseases in which myoblast fusion
defects have been described is DMD16,56,57. Exon skipping with
morpholino antisense oligonucleotides (PMO-AO) is a promising
therapeutic strategy for DMD71. However, sporadic and variable
rescue of dystrophin expression has been reported so far. It was
recently shown that the fusion of PMO-loaded myoblasts to the
repairing myoﬁber is a crucial aspect for PMO delivery into
muscles of mdx mice18. Interestingly, we found a signiﬁcant
reduction of Ash1L expression in muscle tissue from both DMD
patients and mdx mice. In line with a role of Ash1L in activating
myoblast fusion and of its downregulation in DMD, it would be
intriguing to test whether Ash1L co-delivery could increase the
efﬁcacy of PMO for the treatment of DMD.
In conclusion, we deﬁned a key regulatory mechanism of
myoblast fusion, a process required for muscle formation and
repair. A better understanding of Ash1L-mediated regulation of
myogenesis could contribute to clarify pathogenic mechanisms as
well as to improve therapeutic approaches for muscle diseases.
Methods
Mouse handling. All animal procedures were approved by the Institutional Ani-
mal Care and Use Committee of IRCCS San Raffaele Scientiﬁc Institute and were
communicated to the Italian Ministry of Health and local authorities according to
Italian law.
Wild-type C57BL/6J mice were purchased from Charles River (Calco, Italy) and
sacriﬁced at E16.5, P7, P14, P21, and P28. Muscles from the entire hindlimb of
these mice were dissected for RNA extraction and gene expression analysis. To
induce muscle injury, 30 µl of CTX (0.1 mM) (Sigma) were injected into tibialis
anterior muscles of 2-month-old wild-type males, using a 29 G syringe. Mice were
sacriﬁced 5 or 10 days after injury.
Ash1L GeneTrap heterozygous mice were generated by using SIGTR ES cell line
AL0395, carrying an insertion of pGT0lxr vector in Ash1L gene. We aggregated the
ES cell line with 8-cell-stage embryos of the of C57BL/6J background, then the
embryos were transplanted into oviducts of recipients of the ICR background to
generate chimera mice. We performed more than 20 backcrosses in the C57BL/6J
background. Homozygous mutant C57BL/6J embryos were generated by
brother–sister heterozygous mating and analyzed at 18.5 days post coitum.
Ash1L+/+ from the same litter were used as control. Animals of both sexes were
used for the study.
Histology and immunoﬂuorescence. Hindlimbs of 18.5 embryos were dissected,
frozen in isopentane, and cryosectioned at 8 μm thick.
Slices were ﬁxed in 4% paraformaldehyde (PFA, Electron Microscopy Science)
for 10 min, washed with phosphate-buffered saline (PBS), and stained with Harris
hematoxylin for 5 min. After extensive washes with tap water, slices were stained
with Gomori-trichrome solution (Cromotrope 2R 0.6%, Fast Green FCF 0.3%,
phosphotungstic acid 0.6%, acetic acid (glacial) 1% (all from Sigma), pH 3.4) for 10
min, washed in tap water, and dehydrated with ethanol scale and xylene, and then
mounted in xylene-based mounting medium.
Transverse sections were used to evaluate the CSA of myoﬁbers. The analysis
was performed using ImageJ software (http://imagej.net/Downloads)72.
For myoﬁbers nuclei counting, longitudinal sections were ﬁxed in 4% PFA
(Electron Microscopy Science), and then incubated with rabbit anti-laminin
(Sigma, 1:300). Alexa Fluor 488 goat anti-rabbit was used as secondary antibody.
Nuclei were stained by Hoechst 3342. Myonuclei in a single myoﬁber were counted
and normalized to the length of the myoﬁbers72.
For Ash1L immunostaining on muscle sections, CTX-injured and control
muscles of adult wild-type mice were cryosectioned at 8 μm thick. Transversal
sections were ﬁxed in 4% PFA (Electron Microscopy Science). Sections were
permeabilized with Triton X-100 0.2% in PBS and antigen retrieval was performed
using TE buffer, pH 9. Sections were then blocked and incubated with anti-Ash1L
(Bethyl Laboratories; dilution 1:200). Alexa Fluor 488 goat anti-rabbit was used as
secondary antibody. Nuclei were stained by Hoechst 3342.
For Ash1L immunostaining on C2C12, cells were incubated with CSK buffer
(100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES (pH 6.8)) 10 min on
ice, washed with cold PBS, ﬁxed in 4% PFA, and immunostained with Ash1L
antibody (Bethyl Laboratories; dilution 1:200) followed by Alexa Fluor 488 goat
anti-rabbit (Molecular Probes; dilution 1:500) and Hoechst (1 mg/ml; Sigma;
dilution 1:2000).
Pictures were visualized and acquired using Imager.M2 or Observer.Z1 (Zeiss)
microscopes. ImageJ software was used for the analysis. Adobe Photoshop C5 was
used to compose the ﬁnal pictures.
Antibodies are listed in Supplementary Table 1.
Satellite cell-derived primary muscle cell cultures. Cell preparations were col-
lected from the entire hindlimb and forelimb of E18.5 embryos. The skin was
removed, and the limbs were minced and digested at 37 °C with 1.15 mg/ml of
collagenase type IV (Sigma) and 0.4 mg/ml dispase (Life Technologies) for 20 min.
Tissue was ﬁltered through 70 and 40 μm cell strainer and blood cells were lysated
by ammonium chloride (Stem Cell Technologies). Cells were collected by cen-
trifugation and resuspended in nutrient mixture F-10 Ham (Sigma) supplemented
with 20% fetal bovine serum (FBS) (Hyclone), 1% penicillin–streptomycin, 1%
glutamine (Gibco), 0.1% gentamicin (Sigma), and 5 ng/ml basic ﬁbroblast growth
factor (Preprotech). Then, cells were plated on collagen-coated dishes, after 30 min
pre-plating in uncoated dishes (three incubations). Primary myoblasts were grown
for 2 days and then differentiated in Dulbecco’s modiﬁed Eagle's medium (DMEM;
EuroClone) supplemented with 5% donor horse serum (EuroClone) for 48 h. Cells
were collected and RNA extraction was performed using ReliaPrep RNA cell
miniprep system (Promega).
Mammalian cell culture. All procedures involving human samples were approved
by IRCCS San Raffaele Scientiﬁc Institute Ethical Committee. Human primary
myoblasts from healthy donors were obtained from the University of Massachu-
setts Medical School Senator Paul D. Wellstone Muscular Dystrophy Cooperative
Research Center for FSHD (http://www.umassmed.edu/wellstone/) in Worcester
(MA, USA). Human primary myoblasts were grown in in 0.1% gelatin-coated
dishes, in Ham’s F-10 (Sigma-Aldrich) supplemented with 20% FBS, 0.5% chicken
embryo extract, 1.2 mM CaCl2 (Sigma-Aldrich), and 1% penicillin/streptomycin
(100 U/ml ﬁnal concentration; EuroClone). When 90% conﬂuent, cells were
switched to differentiation medium (4:1 DMEM:Medium 199 supplemented with
2% HS (donor horse serum; EuroClone), and 1% penicillin/streptomycin) for
4 days.
Murine C2C12 cells were cultured in DMEM supplemented with 10% FBS and
1% penicillin/streptomycin. For differentiation experiments, C2C12 cells were
plated at 80% conﬂuence in collagen-coated dishes and were differentiated for
3 days in DMEM containing 2% HS (EuroClone).
Human and murine muscle cells were routinely cultured in low oxygen (5%)
conditions. For fusion index quantiﬁcation, cells were ﬁxed in 4% PFA and
immunostained for Mhc with mouse MF20 antibody (Developmental Studies
Hybridoma Bank; dilution 1:2) followed by Alexa Fluor 488 goat anti-mouse
(Molecular Probes; dilution 1:500) and Hoechst (1 mg/ml; Sigma; dilution 1:2000).
Samples were visualized using Observer.Z1 (N-Achroplan ×10/0.25 NA Ph 1)
microscope (Zeiss). Fusion index analysis was performed with ImageJ by counting
the number of nuclei belonging or not to myotubes (myosin-positive syncytia
containing at least three nuclei). Nuclei number distribution was evaluated by
counting the number of nuclei belonging Mhc-positive cells. At least three
independent differentiation experiments were performed. For each experiment at
least six ﬁelds were analyzed, counting at least 1000 nuclei for each cell type.
Transient transfection. For KD experiments, 90,000 cells were plated in each well
of a 6-well plate. The day after, cells were transfected with small interfering RNAs
(siRNAs) against Ash1L or non-targeting control siRNAs [SMARTpool: ON-
TARGETplus ASH1L siRNA L-020460 (human), L-041891 (mouse) or Non-
Targeting Pool D-001810; Dharmacon], using Lipofectamine 3000 reagent
(Thermo Fisher Scientiﬁc) following the manufacturer’s instructions. The day after,
cells were placed in the differentiation medium. The day after, a second transfec-
tion with Ash1L or non-targeting control siRNAs was performed. Cells were ﬁxed
for immunoﬂuorescence assay at day 3 of differentiation.
For rescue experiments, 50,000 cells were plated in each well of a 6-well plate.
The day after, cells were transfected with Ash1L or non-targeting control siRNAs as
above. The day after, proliferating cells were transfected with the pBABE-Cdon
plasmid provided by Dr. Patrick Mehlen (University of Lyon, France) or pBABE-
empty vector control using Lipofectamine LTX (Thermo Fisher Scientiﬁc). After
overday incubation, the transfection medium was replaced with differentiation
medium. Cells were ﬁxed for immunoﬂuorescence at day 3 of differentiation.
Proliferation and migration assays. For the proliferation assay, C2C12 cells were
plated at the density of 2500 cells/cm2. The day after, the transient transfection
with siRNAs was performed as described above. Cells were counted every 9 or 15 h
until 100% of conﬂuence was reached. Doubling times were evaluated as follow:
DT= (duration)Log(2))/((Log(ﬁnal concentration)− Log(initial concentration)).
For the migration assay, C2C12 cells were transfected with siRNAs as described
above. At the density of 60%, images were recorded every 5 min for 4 h, using Zeiss
Axiovert S100 with Hamamatsu OrcaII-ER. Three ﬁelds with ×10 magniﬁcation
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were analyzed for each condition, and 11 mononucleated cells were tracked for
each ﬁeld. The mean of the total distance covered by each cell of the ﬁeld were
evaluated and converted from pixel to μm. The results are expressed as mean of
three independent experiments, for a total of 99 cells per condition.
RNA extraction and RT-qPCR analysis. Total RNA from muscle cells and tissues
was extracted and treated with DNase 1, using RNA spin columns (PureLink RNA
Mini Kit, Ambion) and Trizol reagent (Thermo Fisher Scientiﬁc), respectively.
Complementary DNA (cDNA) was synthesized using Invitrogen’s SuperScript III
First-Strand Synthesis SuperMix. qPCRs were performed with SYBR GreenER
qPCR SuperMix Universal (Invitrogen) using CFX96 Real-Time PCR Detection
System (Bio-Rad). Relative quantiﬁcation was calculated with CFX Manager
Software V.1.6. Glyceraldehyde 3-phosphate dehydrogenase was used as house-
keeping gene for sample normalization. Primers were designed using Primer3 tool
(http://primer3.ut.eu) and are listed in Supplementary Table 1.
Western blot analysis. Protein extracts from C2C12 cells were obtained using
Laemmli buffer 2×. Murine muscle tissue (hindlimbs from both wild-type and
Ash1L GT embryos E18.5) was incubated in RIPA buffer (10 mM Tris-HCl, 1 mM
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxicolate, 0.1% sodium
dodecyl sulfate (SDS), 140 mM NaCl, 1 mM phenylmethanesulfonyl ﬂuoride), then
it was disrupted and homogenized using TissuLyser (Qiagen) for 3 min at 50 Hz,
incubated 30 min on ice, and centrifuged at maximum speed 10 min at 4 °C. The
supernatant was supplemented with Laemmli buffer.
Cell extracts were separated on 6 or 10% SDS-polyacrylamide gel
electrophoresis gels, and then transferred to nitrocellulose membranes. Membranes
were incubated with the antibodies listed in Supplementary Table 1. For detection,
ﬁlters were incubated for 5 min with horseradish peroxidase chemiluminescent
substrate (SuperSignal West Pico Chemiluminescent Substrate; Thermo Fisher
Scientiﬁc). Antibody anti-vinculin was used as a loading control. Uncropped
immunoblot images from representative experiments are shown in Supplementary
Figure 5.
Chromatin immunoprecipitation. Chromatin from C2C12 cells (untreated or
transiently transfected with siRNAs as previously described) was collected at day 1
of differentiation. Cross-linking was performed directly adding to the medium
formaldehyde (Sigma-Aldrich) to the ﬁnal concentration 1% and incubating cells
with gentle swirl 10 min at room temperature (RT). After formaldehyde quenching
with 125 mM glycine (Sigma-Aldrich) for 5 min, cells were washed with PBS and
harvested by scraping and pelleted. Each cell pellet derived from one 15 cm dishes
was lysed in 1 ml of LB1 solution (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl,
1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100; all from Sigma-
Aldrich) for 10 min on ice. The samples were centrifuged at 1350 × g for 5 min at
4 °C. The resulting pellet was washed in 1 ml of LB2 solution (10 mM Tris-HCl, pH
8; 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA; all from Sigma-Aldrich) with
gentle swirl 10 min at RT. Next, samples were centrifuged at 1350 × g for 5 min at
4 °C and the resulting pellet was lysed in 1 ml of LB3 solution (10 mM Tris-HCl,
pH 8; 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, 0.5% N-
laurylsarcosine; all from Sigma-Aldrich). LB1, LB2, and LB3 solutions were sup-
plemented with protease inhibitor (Complete EDTA-free Protease Inhibitor
Cocktail Tablets; Roche). Lysates were sonicated with Bioruptor (Diagenode).
Brieﬂy, 1 ml aliquots of LB3 lysates in 15 ml polystyrene tubes were sonicated for
two rounds of 10 min each (high intensity, 30 s on–30 s off). Before the pre-
cipitation step, Triton X-100 (Sigma-Aldrich) was added to chromatin samples at a
ﬁnal concentration of 1%. For Ash1L and its control, 50 μg of chromatin were
diluted in a ﬁnal volume of 800 μl in LB3 buffer and incubated with 10 μg of
antibody overnight at 4 °C in rotation. For both histones and histone modiﬁcations,
25 μg of chromatin plus 5 μg of antibody were used. The equivalent of 10% of single
IP was collected as input fraction.
The day after, Dynabeads protein G (Thermo Fisher Scientiﬁc) were washed
three times with 0.5% bovine serum albumin (BSA) (Jackson Immunoresearch) in
PBS and 50 μl of washed beads were added to each sample and let for 3 h at 4 °C in
rotation. Then, ﬁve washes with buffer 1 (2 mM EDTA, 20 mM Tris-HCl, pH 8, 1%
Triton X-100, 150 mM NaCl, 0,1% SDS; all from Sigma-Aldrich) and four washes
with buffer 2 (2 mM EDTA, 20 mM Tris-HCl, pH 8, 1% Triton X-100, 500 mM
NaCl, 0.1% SDS; all from Sigma-Aldrich) were performed. Before the elution step,
an additional wash with TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA; all from
Sigma-Aldrich) was performed. Next, samples were centrifuged for 2 min at
1000 × g at 4 °C. The supernatant was discarded and 250 μl of elution buffer (TE
buffer with 2% SDS) were added to the beads–antibody–chromatin complex.
Samples were incubated in a thermo mixer for 15 min at 65 °C while shaking, and
then centrifuged for 1 min at RT at 16,360 × g. The supernatant was transferred to a
new tube and samples, together with the input fractions to which 170 μl of elution
buffer were added (ﬁnal volume 250 μl), were cross-link reverted overnight at
65 °C. The day after, samples were incubated 1 h at 55 °C with 5 μl of Proteinase K
(stock 20 mg/ml; Promega). For DNA puriﬁcation, the QIAquick PCR Puriﬁcation
Kit was used (Qiagen), following the manufacturer’s recommendations. DNA was
eluted in 50 μl of TE buffer and 1 μl was analyzed in quantitative real-time PCR
with the Sybr GreenER qPCR Kit (Thermo Fisher Scientiﬁc). Primers and
antibodies used for ChIP-qPCR analysis are listed in Supplementary Table 1.
RNA-sequencing. Total RNA was extracted using RNA spin columns (PureLink
RNA Mini Kit, Ambion). RNA quantiﬁcation was carried out using Qubit
Fluorimetric Quantiﬁcation (Life Technologies) and 500 ng of RNA were used to
prepare the library. Library generation was performed using QuantSeq 3′ mRNA-
Seq Library Prep Kit. The procedure was initiated by oligo-dT priming, then the
ﬁrst-strand synthesis, and RNA removal was followed by random-primed synthesis
of the complementary strand. The resulting double-stranded cDNA was puriﬁed
with magnetic beads, in order to remove all reaction components. The adapter
sequences were added by library PCR ampliﬁcation, the proper cycle number was
previously determined by qPCR. The library was puriﬁed from PCR components
using puriﬁcation beads. Finally, the quality of the samples was determined using
Bioanalyzer (Agilent Technologies).
Libraries were ﬁnally sequenced using an Illumina HiSeq 2500 system based on
standard protocols (100 bp single end).
Raw sequencing reads (FASTQ) were processed individually and mapped to the
mouse genome reference version GRCm38 (mm10) from Gencode (M13). The
mapping was performed using STAR (v2.5.3a) (https://github.com/alexdobin/
STAR/) using soft clipping and all other parameters set to default values according
to recommended data analysis workﬂow by Lexogen. Gene abundance was
determined using featureCounts (http://bioconductor.org/packages/release/bioc/
html/Rsubread.html) and normalized using calcNormFactors function from edgeR
R/Bioconductor package (http://bioconductor.org/packages/release/bioc/html/
edgeR.html) followed by differential gene expression analysis using LIMMA
(http://bioconductor.org/packages/release/bioc/html/limma.html) on a design
including myoblasts and myotubes for both NS and Ash1L KD (n= 3 each group).
Genes were considered as expressed when showing more than 1 cpm (count per
million) and differentially expressed when showing an FDR < 0.1.
ChIP-sequencing. ChIP samples from C2C12 cells at day 1 of differentiation were
obtained under conditions described above. DNA was further sonicated after
elution, using the Ultra-Sonicator E220 (Covaris) at 10 V for 90 s, and the frag-
ments sizes were evaluated by the Bioanalyzer (Agilent Technologies). ChIP-seq
libraries were prepared using the Accel-NGS 2S Plus DNA Library Kit (Swift
Biosciences), according to the protocol for DNA <10 ng. During Ligation I step, a
unique indexed adapter (SI-ILM2S) was added to label each library. After the post-
ligation II SPRI phase, a qPCR ampliﬁcation was performed using KAPA Library
Quantiﬁcation Kit (Illumina Platforms), to determine the average size-adjusted
concentration of the samples. An extra step of ampliﬁcation was performed at 12
cycles for all the samples with the exception of input and total H3, to reach a
proper concentration for sequencing.
Libraries were sequenced by Macrogen biotechnology company (www.
macrogen.com/eng/) using Illumina HiSeq and analyzed with standard pipelines.
Brieﬂy, reads were checked for quality parameters with FastQC (ref) and trimmed
for adapter content and base quality (≥30). They were aligned to the mouse genome
(mm10) with BWA-MEM (https://arxiv.org/abs/1303.3997) and PCR duplicates
were removed with Picard tools (https://broadinstitute.github.io/picard/). Properly
paired and uniquely mapped reads were additionally cleaned by the removal of
blacklisted regions (https://www.encodeproject.org/) and ﬁnally Ash1L binding
narrowPeaks and broadPeaks were called for the three triplicate samples with
MACS2 callpeak software (https://github.com/taoliu/MACS) (q value < 0.05, slocal
2000) using the Input sample as control. Broad peaks called (q < 0.05) in either of
the three replicates were merged using bedTools (https://bedtools.readthedocs.io/en/
latest/) and annotated to genes by their distance to TSS using the ensemble
annotation (version_oct2016) and R/Bioconductor package (ChIPpeakAnno)
(http://bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html).
Enrichment of Ash1L peaks. Enrichment of Ash1L peaks detected in the ChIP
experiment was made ﬁrstly against classically deﬁned genomic regions (pro-
moters, 5′-untranslated region (UTR), 3′-UTR, coding sequence, introns) (Fig. 5b).
The different regions were downloaded from the UCSC Genome Table Browser
(mm10) and the intersection was calculated using bedtools intersect (at least a 10%
of intersection between the regions and the peaks). The relative enrichment was
calculated by dividing the Ash1L peaks overlap relative fractions of the different
regions by their equivalent genome-wide relative fractions.
For the chromHMM enrichment in Fig. 5c, a union of all chromatin segments
for the available mouse tissues from ENCODE63 was used to ﬁnd the overlap with
Ash1L peaks because of the absence of mouse muscle tissue chromatin
segmentation data. The overlap and relative enrichment were then calculated in the
same way as for the classically deﬁned regions in Fig. 5c.
The proﬁle of Ash1L ChIP-seq coverage around the TSS was calculated by using
scaled regions (to 3 kb) of the 45 direct targets of Ash1L as determined by ChIP-seq
and RNA-seq using deeptools2 plotProﬁle tool (https://deeptools.readthedocs.io/
en/develop/).
H3K36me2 ChIP-seq analysis. Reads coming from H3K36me2 ChIP-seq were
processed similarly to Ash1L ChIP-seq reads. The levels of H3K36me2 methylation
were extracted from the alignments using BedTools (https://bedtools.readthedocs.
io/en/latest/)]. They were then normalized to library size, genome size, and to the
anti-H3 IP control sample levels and averaged between three replicates. The levels
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shown in Fig. 5d were calculated using the mouse annotation ﬁle from gencode (all
genes) or after ﬁltering it for genes expressed in myoblasts as determined by the
RNA-seq experiment (expressed genes) or genes annotated with an Ash1L peak as
detected by the Ash1L ChIP-seq experiment (ChIP-seq peaks). The gene body was
considered from the 5′ end of the most upstream transcript to the 3′ end of the
most downstream transcript of the gene as present in the current annotation.
Violin plots were used using ggplots2 R package.
Gene set enrichment analysis. GSEA (http://software.broadinstitute.org/gsea/
index.jsp) used GSEAPreranked with default parameters using the log 2 fold
changes calculated by LIMMA (http://bioconductor.org/packages/release/bioc/
html/limma.html) on the Ash1L-KD effect (KD vs. NS) in myoblasts and the set of
146 genes identiﬁed as potential Ash1L targets by ChIP-seq.
Functional enrichment. Enrichr web tool (http://amp.pharm.mssm.edu/Enrichr/)
was used to test for functional enrichment with special focus on KEGG, Biocarta,
Reactome, and Wikipathways databases (2016) for pathway enrichment and Gene
Ontology Biological Processes, Molecular Function, and Cellular Components
(2015) for ontologies. ChEA (ChIP-Seq Enrichment Experiment Database, 2016)
was used to explore enrichment in DNA-binding factors. Categories were con-
sidered enriched when shown an FDR <0.05, a Z-score <−1.75 and 3 or more
genes in overlap.
LIMMA analysis (http://bioconductor.org/packages/release/bioc/html/limma.
html) through GEO2R was used to test for activation of Ash1L targets during
muscle differentiation of C2C12 cells. The following conditions were compared:
90% conﬂuency vs. 50% conﬂuency and day 1 vs. 50% conﬂuency in GSE11415; 24
vs. −24 h and 0 vs. −24 h in GSE17039; day −1 vs. day −2 and day 2 vs. day −2 in
GSE989. All comparisons were done in triplicate. In each comparison the probe
sets that were upregulated and downregulated with FDR <0.05 were identiﬁed. A
gene was deﬁned as upregulated if at least one of its probe sets was upregulated in
one comparison and if the number of its probe sets upregulated across all
conditions was greater than the number of downregulated ones. Then, a Fisher
exact test was used to evaluate the enrichment of upregulated genes in Ash1L
targets, with respect to genes that have an Ash1L ChIP peak, but do not show
differential expression in our experiments.
Statistical analysis. Unless stated otherwise, statistical comparisons were two-
tailed tests and performed using GraphPad Prism5.0a (GraphPad Software). The
type of statistical test and the number of independent experiments is provided for
each dataset in the corresponding ﬁgure legend. The differences were considered
statistically signiﬁcant when p ≤ 0.05 and was reported as follows: ****p≤
0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
Data availability
The source data underlying Figs. 1a, 1b, 1c, 1d, 2a, 2b, 3a, 3b, 3c, 7a, 7b, 7c, 7d, 7e,
7f, 8b, 8c and Supplementary Figures 1, 2, 3a, 3b, 3c, 4a and 4b are provided as a
Source Data ﬁle. RNA-seq of myoblasts and myotubes in control and Ash1L-
knockdown muscle cells and ChIP-seq for Ash1L and H3K36me2 and controls
have been deposited in the GEO database under accession code GSE110957. The
muscle tissue differentiation datasets GSE11415, GSE17039, GSE989 were re-
analyzed after downloading from GEO database. Other data and materials are
available from the corresponding author upon reasonable request.
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